Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas
暂无分享,去创建一个
C. James | J. Sarkaria | D. Scholtens | C. Horbinski | S. Mirkov | B. Wray | Kathleen McCortney | M. Drumm | D. Unruh | A. Saratsis | R. Javier | Yuping D. Li | J. Lamano | Qazi F Haider
[1] L. Huang,et al. Friend or foe—IDH1 mutations in glioma 10 years on , 2019, Carcinogenesis.
[2] D. Scholtens,et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers , 2019, Scientific Reports.
[3] M. Mikuła,et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma , 2018, Journal of Cancer.
[4] James J. Morrow,et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence , 2017, Nature Medicine.
[5] Pedro P. Rocha,et al. Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. , 2017, Cell reports.
[6] Steven J. M. Jones,et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 , 2017, Proceedings of the National Academy of Sciences.
[7] D. Kondziolka,et al. Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.
[8] A. Azmi,et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. , 2015, Seminars in cancer biology.
[9] Darrell,et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.
[10] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[11] L. Montermini,et al. The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. , 2014, Biochemical and biophysical research communications.
[12] R. Ammendola,et al. Cell-Surface Receptors Transactivation Mediated by G Protein-Coupled Receptors , 2014, International journal of molecular sciences.
[13] A. Iafrate,et al. Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas , 2014, Clinical Cancer Research.
[14] G. Bourque,et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations , 2014, Proceedings of the National Academy of Sciences.
[15] M. Ross,et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.
[16] T. Mak,et al. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.
[17] T. Helleday,et al. 5-Aza-2′-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair , 2013, Nucleic acids research.
[18] C. Horbinski. What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.
[19] A. Vazquez,et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. , 2013, Cancer research.
[20] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[21] G. Nikkhah,et al. Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. , 2012, Cancer letters.
[22] R. Pieper,et al. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. , 2012, Cancer research.
[23] Peter A. Jones. Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.
[24] Z. Culig,et al. Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer , 2012 .
[25] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[26] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[27] S. Weiss,et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.
[28] P. Reitsma,et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. , 2012, Blood.
[29] W. Ruf,et al. Tissue factor and cell signalling in cancer progression and thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.
[30] T. Shibata,et al. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.
[31] P. Liberski,et al. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions , 2011, British Journal of Cancer.
[32] J. Rak,et al. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. , 2010, Blood.
[33] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[34] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[35] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[36] E. Conway,et al. Coagulation and innate immune responses: can we view them separately? , 2009, Blood.
[37] Erwin G. Van Meir,et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. , 2009, Cancer research.
[38] A. Guha,et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. , 2008, Cancer research.
[39] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[40] Keith D. Robertson,et al. DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B , 2007, Molecular and Cellular Biology.
[41] C. James,et al. Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.
[42] C. James,et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.
[43] H. Prydz,et al. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells , 2004, Thrombosis and Haemostasis.
[44] S. Coughlin,et al. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[45] N. Mackman,et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. , 1989, Biochemistry.
[46] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[47] R. Verhaak,et al. GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.
[48] P. Reitsma,et al. New fundamentals in hemostasis. , 2013, Physiological reviews.
[49] J. Uhm. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .
[50] Zhujun Wang,et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. , 2012, American journal of blood research.
[51] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[52] J. Geng,et al. Tissue factor; from Morawitz to microparticles. , 2007, Transactions of the American Clinical and Climatological Association.